Abstract 2093P
Background
The combination treatment of paclitaxel plus ramucirumab [PACL(W)+RAMU] is a widely accepted option for advanced gastric cancer (AGC) as a second-line chemotherapy to prolong survival. The aim of the study is to identify the validity of bioelectrical impedance analysis (BIA) as a prognosticator in patients receiving PACL(W)+RAMU treatment.
Methods
The study population comprised 189 patients who received PACL(W)+RAMU between Oct. 2019 and Nov. 2022. BIA was conducted at baseline of the PACL(W)+RAMU treatment on all patients and whole body PhA was derived. Continuous variables of other body compartment and blood biochemical values (including complete blood count, serum electrolytes and chemistry) were dichotomized according to the best cut-off values determined by the Contal and O’Quigley methods or the normal values. Kaplan-Meier method and the Cox proportional hazard model were constructed to evaluate the prognostic effect the body component.
Results
Median age of the patients was 59. The cut-off value of PhA was determined as 4.6⁰ at 50 kHz. Median overall survival (OS) of the lower PhA group was 38 weeks (95% CI, 32-45) and 52 weeks (95% CI, 39∼65) for higher PhA group (P=0.021). When combining PhA with obesity degree (current weight/target weight x 100), high phA and low obesity degree (< 116%) demonstrated the favorable OS of 54 weeks (95% CI, 40-68), which contrasts to only 14 weeks (95% CI, 10-18) for low PhA and high obesity degree (≥ 116%) group. In multivariate analysis, the PhA combined with obesity degree is an independent prognosticator for OS (hazard ratio [HR], 6.506 for low PhA and high obesity degree, 95% CI, 3.237-13.076, P<0.001) along with neutrophil-to-lymphocyte ratio and extracellular water.
Conclusions
Bioelectrical impedance component and phase angle could be a useful prognosticator for patients with metastatic gastric cancer. Larger sample size and independent set will be needed to further validate the significance of this study in palliative cancer treatment settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06